Rectiv

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Rectiv

Quick Facts

Property Description
Active ingredient Nitroglycerin (Glyceryl Trinitrate)
Form Topical Ointment (0.4%)
Pharmacological class Organic Nitrate, Vasodilator
Route of administration Topical (Rectal)
Origin Synthetic

What is Rectiv and What Type of Medicine is it?

Rectiv is a medicinal product defined by its active ingredient, Nitroglycerin, which belongs to the high-level pharmacological class of organic nitrates and is categorized as a nitrovasodilator. The active substance, also referred to as Glyceryl Trinitrate (GTN), is a synthetic compound formulated for localized therapeutic effect. This classification signifies that the drug's fundamental action centers on influencing blood vessels and smooth muscle tissue, distinguishing it from medications like simple analgesics. Rectiv is specifically a prescription-only medication, designed for adults, focusing its medicinal action exclusively on the properties derived from its core nitrate compound.

Rectiv's Composition and Specialized Form

The medicine is manufactured as a specialized topical ointment, specifically formulated at a 0.4% concentration and designed for rectal administration. In this formulation, the Nitroglycerin compound is homogeneously suspended in an ointment base—a non-active, lipophilic vehicle—to facilitate localized contact and controlled absorption. The ointment base ensures the concentration of the active ingredient remains targeted to the site of application, maximizing the local action while limiting general systemic exposure. Nitroglycerin operates by serving as a source of nitric oxide (NO), leading to the essential smooth muscle relaxation required for its therapeutic effect.

What is the General Therapeutic Purpose of Rectiv?

The general therapeutic purpose of Rectiv is to facilitate the relaxation of smooth muscle and promote localized vasodilation (widening of blood vessels) in the area of application. The Nitroglycerin is converted locally into nitric oxide (NO), a signaling molecule that causes involuntary muscles, like the internal anal sphincter, to relax. By directly reducing this excessive muscle tension, the drug works to alleviate the discomfort associated with high resting pressure. This action subsequently improves blood flow to the affected tissues, a crucial step that aids in mitigating localized pain and creating an environment conducive to natural healing.

Regulatory References

  1. Nitroglycerin - StatPearls - NCBI Bookshelf

What side effects are possible with Rectiv?

Possible Side Effects and Safety Information

The officially documented safety profile of Rectiv, based on government regulatory labeling, categorizes adverse reactions primarily by frequency and the body system affected.

Classification System-Organ Class (SOC) Examples Specific Adverse Reactions
Very Common Nervous System Disorders Headache (most frequent reaction)
Common Vascular Disorders, Gastrointestinal Disorders Dizziness, Hypotension (low blood pressure), Nausea, Anal Discomfort

Serious Adverse Reactions and Constraints

The regulatory documents specify risks related to the drug's vasodilatory effects. Serious adverse reactions that are documented include profound hypotension (severe drops in blood pressure) and syncope (fainting). A rare but serious hematologic event, Methemoglobinemia, is also listed.

An absolute safety constraint prohibits the use of Rectiv in individuals who are taking phosphodiesterase type 5 (PDE-5) inhibitors (e.g., sildenafil, tadalafil) due to the risk of severe, life-threatening hypotension. The medicine is also restricted for use in patients with conditions such as severe anemia, known hypersensitivity to nitrates, or increased intracranial pressure (e.g., following a traumatic head injury).

Time-Related Patterns and Special Populations

Official labeling states that Headache may be more likely to occur at the start of treatment. Additionally, the safety and effectiveness of Rectiv have not been established in pediatric patients, and older adults may exhibit increased sensitivity to the hypotensive effects of the drug.


Connection to the overall safety profile:

The regulatory safety information structures the understanding of risk by formalizing the very common occurrence of headaches and the potential for cardiovascular effects, such as hypotension, across multiple organ system categories. The profile highlights critical constraints, particularly the absolute restriction against concomitant use with PDE-5 inhibitors and the specific lack of established safety in the pediatric population.

Overdose and Emergency Response

Overdose and when to seek help for Rectiv

Overdose with Rectiv is characterized by the effects of profound vasodilation following excessive systemic exposure to Nitroglycerin. Officially documented manifestations include severe hypotension (a significant drop in blood pressure), a persistent pulsatile headache, dizziness, flushing, and changes in heart rate such as tachycardia.


Severe Outcomes and Emergency Action

Severe or life-threatening consequences are documented in regulatory labeling, including syncope (fainting), circulatory collapse, and seizures. A specific, serious risk is the development of Methemoglobinemia, which compromises blood oxygen transport and may present with cyanosis (bluish skin discoloration).

In all suspected overdose situations, regulatory guidance mandates that patients seek immediate medical attention. Emergency services must be contacted immediately if severe signs such as collapse, loss of consciousness, or seizure activity occur.


Management and Antidote Information

Management is procedural and supportive, as no specific antagonist for the primary vasodilatory effects is known. Officially described supportive measures include discontinuing the drug, elevating the patient's legs, and administering intravenous fluids to manage hypotension. Treatment for the specific complication of Methemoglobinemia, if confirmed, is Methylene Blue.

Therapeutic Uses of Rectiv

What Rectiv Treats: Main Uses and Benefits

Rectiv is a topical medication specifically formulated for the treatment of pain associated with chronic anal fissures. An anal fissure is a small tear or ulcer in the lining of the anal canal, which can cause significant discomfort, particularly during and after bowel movements.

Primary Indication

The primary use of Rectiv is to provide relief from the moderate to severe pain that accompanies chronic anal fissures. A fissure is generally classified as chronic if it has been present for more than six weeks or if it has failed to heal with conservative measures such as increased fiber intake and warm baths.

Mechanism of Action and Benefits

Rectiv contains nitroglycerin, a vasodilator. When applied topically to the affected area, the medication works by relaxing the internal anal sphincter muscle. This relaxation leads to several physiological benefits:

  • Reduction in Muscle Pressure: Chronic fissures are often associated with high resting pressure in the anal canal. By relaxing the sphincter muscle, the medication reduces this pressure, which is a primary source of the pain.
  • Improved Blood Flow: Relaxing the sphincter muscle helps to improve local blood circulation in the anal lining. Enhanced blood flow is a critical factor in supporting the body's natural healing process for the tear.
  • Symptom Management: The decrease in muscle tension and improved circulation collectively help to alleviate the sharp, stabbing, or burning sensations commonly reported by individuals with this condition.

Therapeutic Goals

The use of Rectiv is intended to manage the pain cycle that often prevents healing. By reducing the pain and the associated muscle spasms, the medication creates a more favorable environment for the tissue to repair itself, potentially avoiding the need for more invasive surgical interventions.

Eligibility and Restrictions for Use

Who can and cannot use Rectiv?

The use of Rectiv (nitroglycerin 0.4% ointment) is determined by strict, official population-eligibility rules defined in regulatory documents.

Eligibility and Restrictions

Population Group Eligibility Status
Adults (18+ years) Approved Population for the labeled indication.
Pediatric Patients (<18 years) Safety and effectiveness Not Established.
Older Adults (Geriatric) Use requires Caution, as hypotensive effects may be more pronounced.
Renal/Hepatic Impairment No official restriction or dosage adjustment specified in regulatory labels.

Absolute Contraindications

Rectiv is contraindicated and must not be used in patients with the following conditions or concurrent treatments:

  • Severe Anemia: Due to the risk of severe hypotension.
  • Increased Intracranial Pressure (ICP): Such as that caused by head trauma or cerebral hemorrhage.
  • Hypersensitivity: Known allergy to nitroglycerin, other nitrates, or any ointment component.
  • Concurrent PDE5 Inhibitors: Patients taking medicines like sildenafil, tadalafil, or vardenafil, due to the risk of severe hypotension.

Conditional Use

Caution is advised when treating patients with existing hypotension, blood volume depletion, or underlying cardiovascular conditions such as congestive heart failure.

Pregnancy and Lactation

The regulatory status during pregnancy is undetermined (Category C); use is considered only if the potential benefit justifies the potential risk to the fetus. Excretion into human milk during lactation is unknown.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation structures the interaction profile of Rectiv (Nitroglycerin topical ointment) around specific combinations that are formally prohibited due to the risk of severe blood pressure effects, along with interactions that modify the clearance or therapeutic outcome of co-administered drugs.

Contraindicated Combinations and Timing

The co-administration of Rectiv is strictly contraindicated with Phosphodiesterase Type 5 (PDE5) inhibitors (e.g., Sildenafil, Tadalafil, Vardenafil) and Riociguat. Regulatory labels require that Rectiv must not be used within a few days of using a PDE5 inhibitor, owing to the high potential for life-threatening hypotension.

Pharmacodynamic and Exposure Interactions

The most common documented interactions involve additive hypotensive effects. Co-administration with Antihypertensive Drugs, Beta-adrenergic Blockers, Calcium Channel Blockers, and Other Organic Nitrates/Nitrites may result in a greater-than-expected reduction in blood pressure. An additive vasodilating effect is also documented with alcohol consumption.

Rectiv also affects the exposure or activity of other medicines. Co-administration may reduce the anticoagulant effect of Heparin and the thrombolytic effect of Tissue-type Plasminogen Activator (t-PA). Conversely, the oral bioavailability of drugs like Ergotamine may be increased due to reduced first-pass metabolism.

Mechanism of Action

Molecular Action: The Nitric Oxide Cascade

Rectiv works by acting as a prodrug that is enzymatically converted into the gaseous signaling molecule, Nitric Oxide ( NO), primarily via the enzyme ALDH2 within smooth muscle cells. The NO rapidly activates soluble Guanylate Cyclase ( sGC), leading to a significant increase in the second messenger, cyclic Guanosine Monophosphate ( cGMP). This initial molecular step initiates the cascade that results in smooth muscle relaxation and localized vasodilation.

️ Physiological Effect: Modulating Smooth Muscle Tone

The surge in cGMP activates Protein Kinase G ( PKG), which modulates key contractile enzymes (MLCK and MLCP). This action results in the dephosphorylation of the myosin light chain, which is the final common pathway for smooth muscle relaxation. The core physiological consequence is the resulting decrease in internal anal sphincter smooth muscle tone, alongside local vasodilation in the surrounding tissue.

⏳ Mechanism Constraints: Rate and Tolerance

The efficacy of the mechanism is rate-limited by the availability of the bioactivating enzymes. Furthermore, this NO signaling mechanism is susceptible to tachyphylaxis (tolerance), where sustained exposure can lead to the down-regulation of the enzymes required for NO generation, potentially limiting the achieved degree of smooth muscle relaxation.

Dosage and Administration Information

How to use Rectiv

Rectiv administration follows a standardized approach for its defined course of therapy. The medicine is formulated as a 0.4% topical ointment for intra-anal application. This formulation is indicated for use in adults 18 years of age and older.


Administration Protocol and Dosage

Feature Protocol Detail
Route of Administration Topical application to the anal canal.
Standard Dosing A measured dose of 375 mg of ointment, which delivers 1.5 mg of nitroglycerin.
Frequency and Schedule Applied consistently twice daily, maintaining a 12-hour interval between applications.
Course Duration Intended as a limited course of therapy, typically lasting up to 3 weeks.

Procedural Requirements and Timing

The administration protocol is centered on precision and localized delivery. The standard dose must be accurately measured using the provided dosing guide or card, as the quantity of ointment must not be exceeded. Before application, a finger covering (e.g., a finger cot or glove) is used. The measured quantity is applied to the covered finger and gently inserted and applied circumferentially into the lower part of the anal canal. After administration, the finger covering is disposed of and hands must be thoroughly washed.

If a dose is missed, it is to be applied as soon as it is remembered, provided it is not close to the time for the next scheduled dose. If it is close, the missed dose should be skipped, and the regular 12-hour cycle resumed. This approach establishes a standardized, limited-duration course of therapy.

Recent Clinical Evidence

Summary of Efficacy Findings

Research has explored the drug's effects in the treatment of moderate-to-severe pain associated with chronic anal fissures (CAF). In the key randomized, double-blind, placebo-controlled trial, patients with CAF were randomized to receive the 0.4% nitroglycerin ointment or a placebo ointment.

Studies evaluated whether the ointment was associated with a change in 24-hour average anal fissure pain scores, as measured by a visual analog scale (VAS) over the course of the study. An analysis of the primary trial data suggested that the nitroglycerin ointment was associated with a measurable improvement in pain reduction compared to placebo in the context of the trial.


Administration and Observation

The studies examined administration of the drug at the same time daily, exploring whether this scheduling impacted observed outcomes. Research evaluated the drug's action on specific biological markers, examining whether it influenced the biological pathway by reducing anal sphincter pressure.

The tolerability of the drug was documented in adults in the clinical trials. Headache was the most commonly reported adverse event in the treatment group. Studies were also conducted to assess the drug's pharmacokinetics and findings in adolescents (age 12 to less than 17 years) with CAF.


Outcomes in Specific Patient Groups

Clinical studies did not include sufficient numbers of older individuals (aged 65 years or older) to determine definitively whether they respond differently from younger individuals. However, literature suggests older adults may demonstrate increased sensitivity to the effects of nitrates, such as hypotension (low blood pressure) and related dizziness or fainting.

Key Studies & References

  1. Nitroglycerin 0.4% ointment vs placebo in the treatment of pain resulting from chronic anal fissure: a randomized, double-blind, placebo-controlled study

Frequently Asked Questions (FAQ)

Common questions about Rectiv (FAQ)


Q: Does Rectiv simply relieve pain, or does it actually help the fissure close?

Official information describes the medication’s action as reducing excessive muscle tension and improving blood flow to the affected area. The combination of these physiological effects is intended to not only help relieve discomfort but also establish an environment that is supportive of the natural healing process of the chronic anal fissure.


Q: Does alcohol consumption affect how Rectiv works or increase side effects?

Regulatory documentation notes that alcohol can have an additive vasodilatory effect when combined with this medicine. Because both substances widen blood vessels, combining them is associated with an increased risk of side effects. These can include headache, dizziness, and low blood pressure.


Q: Is it safe to take over-the-counter pain relief like acetaminophen for Rectiv headaches?

Patient information often mentions that the headaches which occur with the ointment can be managed. Nonprescription pain relievers, such as acetaminophen, are suggested as an option for addressing this common side effect.


Q: Is there any risk of becoming tolerant to the effects of Rectiv over time?

Official information indicates the underlying mechanism is susceptible to a decline in response over time, which is technically referred to as tachyphylaxis or tolerance. Official labeling specifically notes that tolerance to the headache side effect has been observed.


Q: Can Rectiv ointment be applied externally only if internal application is too painful?

Official patient labeling includes instructions for this situation. If the intra-anal application is too painful to perform, the instructions specify that the ointment should instead be applied directly to the outside of the anus.


Q: What should be avoided after application to prevent symptoms of low blood pressure?

Since low blood pressure (hypotension) is a potential side effect, official guidance addresses mitigating related symptoms like dizziness or fainting. Official guidance indicates getting up slowly when rising from a sitting or lying position to help manage these effects.


Q: Is the headache from Rectiv a sign that the medication is working?

According to patient information resources, the headaches that occur after application are sometimes mentioned as a possible indication that the medication is active. This effect is related to the same vasodilating action that targets the underlying condition.


Q: What are the less common side effects of Rectiv ointment?

Beyond the common effects like headache and dizziness, regulatory documents list other less frequent adverse reactions. These may include blurred vision, confusion, excessive sweating, loss of heat from the body, and certain localized skin reactions.


Q: What happens if I accidentally use too much Rectiv ointment?

Using more than the prescribed amount may lead to symptoms that have been associated with using too much of the ointment. These symptoms can include a severe throbbing headache, fainting, confusion, or a fast heartbeat.


Q: Can Rectiv cause a slow heart rate?

Yes, official safety information indicates that the drug may cause a slow heart rate, which is known as bradycardia. This effect is generally possible in conjunction with episodes of low blood pressure (hypotension).


Q: Are there any known interactions between Rectiv and blood thinners like aspirin?

Official regulatory documents report that co-administration of aspirin (at certain doses) can interact with the ointment. This may increase the maximum concentration of nitroglycerin in the body, which could enhance the pharmacological effects of the medicine.


Q: Can Rectiv affect the results of blood or laboratory tests?

The medication’s interaction profile shows that it can affect the action of the anticoagulant drug heparin. Specifically, co-administration may reduce heparin's anticoagulant effect, which requires monitoring of the patient's blood clotting status during treatment.


Q: What should I do if the anal pain does not get better after 3 weeks of using Rectiv?

Official instructions indicate the course of therapy is limited to up to three weeks. If the anal fissure pain continues or does not show improvement after this time, official guidance indicates contacting a doctor for follow-up.


Q: Does the way I apply the ointment affect how well Rectiv works?

Regulatory instructions emphasize a standardized approach to application. This includes using the provided dosing guide for an accurate amount and applying the ointment circumferentially to the anal canal. The rate and extent of medication absorption may vary based on application method.


Q: Is it normal to experience a burning sensation at the application site?

Localized reactions at the site of application are possible with this medicine. The official labeling lists anal discomfort as a common adverse reaction, which may include sensations such as burning.

How should Rectiv be stored and disposed of?

Storage Conditions and Environment

Rectiv (nitroglycerin) Ointment must be stored at Controlled Room Temperature, specifically between 20°C and 25°C (68°F and 77°F). The medication must be kept from freezing and away from excessive heat. To maintain stability, the ointment should be stored away from excess moisture and out of direct light. The container must be kept tightly closed when not in use.

Stability and Child Safety

For child safety, the ointment must be stored out of the reach of children. The product has a defined in-use period: the tube and any remaining ointment must be discarded 8 weeks after the tube is first opened.

Disposal Instructions

Unused or expired Rectiv should not be thrown in household trash or poured down a drain. Disposal must be conducted according to local regulations; patients should consult a pharmacist or healthcare provider on proper disposal methods.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Rectiv found in:

A-Z Index: